The transmembrane glycoprotein CD44, known to bind hyaluronan, selectins, and osteopontin, displays a plethora of functions in healthy and diseased tissues [69] and has been targeted therapeutically in AML before it was described as an LSC marker. The gene discussed is CD44; the disease is acute myeloid leukemia.